Since CXXC5 was highly expressed in some patients with solid tumors, and the expression level of CXXC5 was positively correlated with mTOR signaling pathway, our results demonstrate that targeting CXXC5 is likely to be an effective means of treating cancer patients, such as those receiving immunotherapy, as a biotherapeutic strategy. This evidence concerns the gene CXXC5 and cancer.